These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27100995)

  • 21. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
    Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation.
    Coleman CI; Weeda ER; Nguyen E; Bunz TJ; Sood NA
    Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):328-329. PubMed ID: 29121212
    [No Abstract]   [Full Text] [Related]  

  • 23. [Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
    Divisón Garrote JA; Escobar Cervantes C
    Semergen; 2016; 42(4):260-2. PubMed ID: 26653339
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
    Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
    Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The new oral anticoagulants: Reasonable alternatives to warfarin.
    Roca B; Roca M
    Cleve Clin J Med; 2015 Dec; 82(12):847-54. PubMed ID: 26651894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants.
    Ghiadoni L; Taddei S; Virdis A
    Curr Pharm Des; 2014; 20(39):6096-105. PubMed ID: 24745925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
    Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
    Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country.
    Boietti B; Fili S; Peuchot V; Tabares A; Vázquez F; Gándara E
    Thromb Res; 2021 Aug; 204():143-145. PubMed ID: 33593595
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
    Vamos M; Cappato R; Marchlinski FE; Natale A; Hohnloser SH
    Europace; 2016 Dec; 18(12):1787-1794. PubMed ID: 26797248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of heparin-induced thrombocytopenia with rivaroxaban. Case report].
    Rivera O G; Corsi S O; Pavlovic J A; Aizman S A; Varas A P
    Rev Med Chil; 2017 Sep; 145(9):1213-1217. PubMed ID: 29424412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data on trial of anticoagulant is to be reanalyzed after discovery that investigators used faulty device.
    Cohen D
    BMJ; 2015 Dec; 351():h6431. PubMed ID: 26635138
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C; Dai S; Sobieraj DM
    Int J Cardiol; 2015 Aug; 192():1-2. PubMed ID: 25981569
    [No Abstract]   [Full Text] [Related]  

  • 39. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.
    Barón-Esquivias G; Marín F; Sanmartín Fernandez M
    Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.